Merck Eyes Global Approval, Prisoners Dilemma Cooperation Emerges, HistoSonics Wins Asia Approval, AI Maps Autism and ADHD Paths, and more...

brief.news

19 May 2026

(0:10): Sacituzumab Tirumotecan Boosts Survival in Endometrial Cancer; Merck Eyes Global Approval(2:21): Rutgers Study Reveals Natural Pathways to Cooperation in Prisoner's Dilemma Without Kinship or Rules(3:40): HistoSonics Gains Ground in Asia with TFDA Approval for Edison Histotripsy System(5:24): Swedish Study Expands to Predict Autism, ADHD Trajectories with AI by Age 10(7:54): GlucoBrain: Revolutionizing Diabetes-Dementia Research with 3D Microfluidic BiochipTo subscribe visit https://www.brief.news.For more updates in your inbox each morning visit www.brief.news. Image credit: Rutgers University